Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
X-ray repair cross-complementing protein 6, commonly known as Ku70, is a pivotal DNA-binding protein that forms a heterodimer with Ku80 to initiate the non-homologous end joining (NHEJ) pathway, the primary mechanism for repairing DNA double-strand breaks in mammalian cells [1, 11]. The Ku70/80 complex functions as a molecular scaffold that rapidly recognizes and binds to broken DNA ends, subsequently recruiting the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and other repair factors [2, 14]. Beyond its central role in maintaining genomic integrity, Ku70 is involved in telomere protection, Bax-mediated apoptosis, and acts as a cytosolic DNA sensor that triggers innate immune responses [4, 5]. In the context of oncology, Ku70 is often upregulated in various tumors, where it contributes to therapeutic resistance by efficiently repairing damage caused by ionizing radiation and chemotherapeutic agents [7, 15]. This has led to the development of small-molecule inhibitors, such as STL127705 and UMI-77, which aim to disrupt Ku-DNA interactions and sensitize cancer cells to DNA-damaging therapies [23, 29]. However, therapeutic targeting of Ku70 is complicated by its essential role in normal cell survival and its requirement for V(D)J recombination during immune system development [16, 27]. Additionally, Ku70 is a known autoantigen in systemic autoimmune diseases like lupus and polymyositis, further highlighting its complex biological significance [1, 11].
Inhibition of Ku-DNA binding and disruption of the Ku70/80 heterodimer to block non-homologous end joining (NHEJ) and sensitize cells to DNA-damaging agents.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on X-ray repair cross-complementing protein 6 (Ku70) (Ku70).